Effects of naltrexone on mood and neuroendocrine function in normal adult males
References (28)
- et al.
β-Endorphin and male sexual behavior
Eur. J. Pharm.
(1977) - et al.
Acute effects of heroin and naltrexone on testosterone and gonadotrophin secretion: a pilot study
Psychoneuroendocrinology
(1976) - et al.
Inhibition of the release of pituitary ovulatory hormone in the rat by morphine
Endocrinology
(1955) - et al.
Sexual impotence: a double-blind study of LHRH nasal spray versus placebo
Neuropsychobiology
(1975) - et al.
The pharmacologic blockade of the circhoral mode of LH secretion in the ovariectomized rhesus monkey
Endocrinology
(1972) - et al.
Endorphins: profound behavioral effects in rats suggest new etiological factors in mental illness
Science
(1976) - et al.
Naloxone and related compounds
- et al.
Preclinical toxicity studies of naltrexone
National Institute of Drug Abuse, Research Monograph Series
(1976) - et al.
Intravenous naloxone administration in schizophrenia and affective illness
Science
(1977) - et al.
Degrees and duration of reversal by naloxone of effects of morphine in conscious subjects
Br. med. J.
(1974)
Hyperalgesia induced by naloxone follows diurnal rhythm in responsivity to painful stimuli
Science
Evidence against involvement of endorphins in sexual arousal and orgasm in man
Arch. Gen. Psychiat.
Effects of naloxone on experimentally induced ischemic pain and or mood in human subjects
P.N.A.S.
Endorphins: naloxone fails to alter experimental pain or mood in humans
Science
Cited by (115)
Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder
2018, Drug and Alcohol DependenceCitation Excerpt :Animals who have experienced naltrexone-precipitated opioid withdrawal demonstrate conditioned place aversion and acoustic startle (i.e., anxiety-like behavior) for extended periods of time (Rothwell et al., 2012; Stinus et al., 2000). In humans, multiple studies have shown that opioid-naïve individuals find naltrexone aversive (Hollister et al., 1981; Mendelson et al., 1978). While naltrexone effectively blocks subjective effects from opioids and to a lesser extent from alcohol (Bigelow et al., 2012), it does not alter the subjective-rewarding effects of smoked cocaine, oral amphetamine, or oral or intravenous Δ 9-tetrahydrocannabinol (THC) (Comer et al., 2013; Ranganathan et al., 2012; Wachtel and DeWit, 2000).
LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders
2014, NeuropharmacologyCitation Excerpt :Indeed, there has been little evidence of antidepressant activity in individuals taking naltrexone. To the contrary, naltrexone has been reported to produce dysphoria in both humans and rodents (Mendelson et al., 1978; Hollister et al., 1981; West and Wise, 1988). The concordance of these data with those obtained with long-acting kappa antagonists (nor-BNI and JDTic) adds important and needed support of the hypothesis that kappa opioid receptor blockade might result in antidepressant actions.
A phase 2a multicenter, double-blind, placebo-controlled, crossover trial to investigate the efficacy, safety, and toleration of CP-866,087 (a High-Affinity Mu-Opioid Receptor Antagonist) in Premenopausal women diagnosed with Female Sexual Arousal Disorder (FSAD)
2013, Journal of Sexual MedicineCitation Excerpt :Prosexual effects of nonselective opioid antagonists and antisexual effects of opioid agonists have been reported in the literature. Naloxone (a nonselective opioid antagonist) has been shown to enhance pleasure during orgasm in women, and naltrexone (a mu antagonist and partial agonist for delta and kappa opioid receptors) has been reported to increase the number and intensity of erections in men with normal or abnormal erectile function [23-29]. The aim of this phase 2 study was to prospectively evaluate the effects of CP‐866,087, a selective mu‐opioid receptor antagonist, in premenopausal women with FSAD.
Alcohol abuse: Endocrine concomitants
2009, Hormones, Brain and Behavior OnlineComparing and combining gamma-hydroxybutyric acid (GHB) and naltrexone in maintaining abstinence from alcohol: An open randomised comparative study
2007, European Neuropsychopharmacology